FOLH1 and neoplasm: 177Lu2O3-iPSMA nanoparticles could also be useful in the treatment of hepatocellular carcinoma, where PSMA is expressed both on the membrane of cancer cells (41% of tumors) and in the tumor neovasculature (90% of tumors) [16].